Alembic Pharmaceuticals shares jumped more than 4% in early trade after the company received USFDA approval for Albendazole tablets.
The US Food and Drug Administration (USFDA) granted Alembic Pharmaceuticals Ltd final approval for its 200 mg USP albendazole tablets.
Albendazole tablets are used to treat neurocysticercosis produced by the pork tapeworm and cystic hydatid disease of the liver, lung and peritoneum caused by the dog tapeworm. Alembic now holds 214 ANDA approvals from the USFDA, including 186 final approvals and 28 tentative approvals.
As of 10:15 am, Alembic Pharmaceuticals shares were trading 4.21% higher at Rs 1,152.25 on the NSE.
TOPICS:
Alembic Pharmaceuticals